Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2Metastatic Castrate Resistant Prostate Cancer (mCRPC) 2Salivary Gland Neoplasms 1Bites and Stings 1Adenocarcinoma 1

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Stents 2Neoadjuvant Therapy 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2AMG 757 2soybean oil, phospholipid emulsion 1durvalumab 1dostarlimab 1cemiplimab 1camrelizumab 1atezolizumab 1Surgical Procedures, Operative 1Surgical Instruments 1Radiotherapy, Conformal 1Radiotherapy 1Passive Cutaneous Anaphylaxis 1Palliative Care 1Nephrotomy 1Nephrostomy, Percutaneous 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Morphine 1Lidocaine 1Levobupivacaine 1Immunotherapy 1Hydroxyurea 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bites and Stings × Androgen Receptor Antagonists × Clear all
NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

Phase 1/2 Terminated
65 enrolled

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon âš¡